VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PRQR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PRQRProQR Therapeutics N.V.
$1.15$116M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksPRQRCash Flow

ProQR Therapeutics N.V. (PRQR) Cash Flow Statement

13Y historyFree accessUpdated daily

Operating cash flow was -$12.4M in 2026Q2 and negative in every reported quarter, with free cash flow margins as low as -154.6%, indicating that cash burn persists independent of headline revenue movements and that the revenue spike has not yet translated into cash generation.

Income StatementBalance SheetCash FlowRatios

PRQR Cash Flow Statement

Annual statement

PRQR Cash Flow Statement

ProQR Therapeutics N.V. (PRQR) cash flow statement — 13-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash from Operations-49.14M-52.79M-36.39M21.55M-68.51M-26.01M-47.06M-43.97M-30.68M-34.95M-34.22M-24.23M-14.46M-2.33M
Operating CF Margin %--345.53%-192.5%330.8%-1906.18%-1948.46%-4573.38%-2274.7%-620.97%2285.87%-1499.61%-257.6%-4618.85%-
Operating CF Growth %-138.5%-45.06%-268.89%131.45%-163.37%44.73%-7.03%-43.31%12.21%-2.13%-41.22%-67.61%-519.94%-
Net Income-42.4M-42.18M-27.76M-27.73M-64.2M-60.8M-46.61M-56.75M-37.09M-43.52M-39.12M-20.83M-12.13M-3.25M
Depreciation & Amortization2.76M2.7M2.76M2.51M2.52M2.33M2.35M2.05M992K1.06M1.25M480K126K24K
Stock-Based Compensation3.77M4.01M2.54M3.11M2.87M6.22M7.84M9.11M3.22M4.02M2.45M1.21M646K41K
Deferred Taxes1K19K-197K-78K96K117K124K132K102K145K236K441K142K13K
Other Non-Cash Items1.76M74K-474K-5.21M-4.8M1.11M-5.29M-210K792K3.17M-470K-6.17M-4.33M14K
Working Capital Changes-15.26M-17.42M-13.26M48.96M-4.99M25.01M-5.47M1.69M1.29M164K1.43M637K1.09M829K
Change in Receivables00000000000000
Change in Inventory00000000000000
Change in Payables00000000000000
Cash from Investing-1.15M-1.02M-4.07M4.28M-702K-425K-924K-580K-312K-121K-2.54M-1.32M-1.23M-137K
Capital Expenditures-1.15M-1.02M-1.42M-1.37M-708K-484K-924K-580K-312K-121K-2.54M-1.32M-1.23M-137K
CapEx % of Revenue6.21%6.68%7.5%21.05%19.7%36.25%89.8%30.01%6.31%-7.91%111.26%14.07%393.93%-
Acquisitions00000000000000
Investments--------------
Other Investing00-2.65M5.65M6K59K00000-28K00
Cash from Financing48.04M-1.84M70.28M-2.27M-30.89M136.83M14.5M50.2M88.65M26.64M357K1.62M119.88M6.35M
Debt Issued (Net)-1.97M-1.91M-1.58M-2.63M-45.05M26.84M13.77M1.46M1.4M951K355K1.61M1.63M3.33M
Equity Issued (Net)50.02M69K71.64M014.12M108.48M048.55M84.19M25.68M00118.25M3.02M
Dividends Paid00000000000000
Share Repurchases00000000000000
Other Financing-8.36K0223K354K34K1.52M735K193K870K4K2K14K00
Net Change in Cash-3.29M-56.99M30.48M24.15M-92.75M111.69M-36.11M6.37M57.48M-11.1M-35.66M-17.87M108.61M3.88M
Free Cash Flow-50.29M-53.81M-37.81M20.18M-69.22M-26.5M-47.98M-44.55M-30.99M-35.07M-36.76M-25.56M-15.69M-2.47M
FCF Margin %-270.78%-352.21%-200.01%309.75%-1925.88%-1984.72%-4663.17%-2304.71%-627.28%2293.79%-1610.87%-271.67%-5012.78%-
FCF Growth %-17.1%-42.32%-287.4%129.15%-161.23%44.78%-7.71%-43.74%11.63%4.59%-43.84%-62.88%-535.48%-
FCF per Share-0.46-0.51-0.460.25-0.97-0.41-0.96-1.09-0.91-1.38-1.57-1.09-0.71-0.11
FCF Conversion (FCF/Net Income)1.19x1.30x1.31x-0.77x1.06x0.43x1.01x0.77x0.83x0.80x0.88x1.16x1.19x0.72x
Interest Paid00000000000000
Taxes Paid00000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Persistent operating cash burn

Cash Burn Exceeds Reported Losses

According to the reported cash flow data, PRQR's operating cash flow was negative in every one of the ten quarters, with the ratio of operating cash flow to net income ranging from 0.70 to 2.32, indicating cash losses that frequently run ahead of or alongside accounting losses.

Because net income and operating cash flow are both negative in each period, the ratio is mechanically less informative than the absolute gap, which in several quarters such as 2024Q2 and 2026Q2 shows operating cash outflows larger than reported losses. This pattern suggests working capital movements and collaboration timing may be amplifying cash consumption relative to earnings. Investors should monitor whether the 2026Q2 revenue spike converts into actual cash receipts, since the absence of such conversion would widen the cash gap further.

Free Cash Flow Deeply Negative Throughout

As reported in the cash flow statements, PRQR's free cash flow was negative across all ten quarters, reaching -$16.0M in 2025Q1 and -$12.7M in 2026Q2, with free cash flow margins frequently falling below -100% in periods of low revenue.

The persistence of negative free cash flow across a full decade indicates that the business has not yet reached a level of operating scale capable of funding its research spend internally. The extreme negative margins in quarters such as 2026Q2 reflect the small revenue base relative to fixed cash outlays rather than a deteriorating cost structure alone. Without a sustained revenue step-up, the trajectory implies continued reliance on external balance sheet resources.

Minimal Capital Intensity Despite Spikes

Based on reported figures, PRQR's capital expenditure remained small in absolute terms, between roughly $0.1M and $0.7M per quarter, though the capex-to-revenue ratio spiked to 16.4% in 2024Q1 when revenue was comparatively low.

Low absolute capex relative to the cash burn indicates that the cash drain is driven primarily by operating expenses, chiefly research and development, rather than by physical asset investment. The elevated capex-to-revenue readings in periods of weak revenue reflect denominator effects rather than heavy investment programs. This suggests the company's capital requirements are largely tied to clinical and operating spend rather than to facilities.

Working Capital Swings Drive Volatility

As reported in the working capital line, PRQR's working capital change ranged from a $9.2M outflow in 2024Q1 to a $1.1M inflow in 2024Q3, with several quarters showing large swings that appear to account for much of the quarter-to-quarter variance in operating cash flow.

The magnitude of working capital movements relative to reported net losses suggests timing of collaboration receivables and payables is a material driver of reported operating cash flow. Such swings indicate that quarterly cash results may be poorly indicative of underlying run-rate burn. Investors would benefit from examining the composition of these movements before drawing conclusions about the sustainability of cash generation.

Revenue Spike May Not Reflect Cash

Based on reported figures, the 2026Q2 revenue jump may prove non-recurring, and the quarter still recorded operating cash flow of -$12.4M, suggesting headline revenue gains have not translated into cash generation.

A bullish reading of the latest revenue increase would need to show collections following recognition, which the cash data does not yet demonstrate. The data does not disclose the nature of the collaboration income, so its durability cannot be assessed from these figures alone. Until operating cash flow turns sustainably positive, the revenue improvement should be treated as analytically uncertain.

PRQR — Frequently Asked Questions

Quick answers to the most common questions about buying PRQR stock.

How much cash does ProQR Therapeutics N.V. (PRQR) generate from operations?

ProQR Therapeutics N.V. (PRQR) generated $-52.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is ProQR Therapeutics N.V.'s free cash flow?

ProQR Therapeutics N.V. (PRQR) reported negative free cash flow of $53.8M in 2025, indicating capital requirements exceeded cash from operations.

What is ProQR Therapeutics N.V.'s capital expenditure (CapEx)?

ProQR Therapeutics N.V. (PRQR) spent $1.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.